Johnson & Johnson To Stop Selling Talc-Based Powder
Johnson & Johnson (NYSE:JNJ) said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move amid…
These 2 Dividend Aristocrats Have Increased Dividend Yields For Over 60 Years
Dividend aristocrats are companies that are in the S&P 500 and have increased annual dividend payments for the past 25 years. These companies typically offer products that will be bought even during times of recession.
These 3 Dividend Yielding Stocks Are Warren Buffett’s Top-Owned Positions In Berkshire
When looking for consistent stocks that offer dividends, Warren Buffett’s Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) can offer a roadmap for those looki
Cardinal Health Names New Chief Executive, Posts Mixed Q4 Earnings
Cardinal Health Inc (NYSE:CAH) has reported Q4 FY22 adjusted EPS of $1.05, up 36% Y/Y, missing the consensus of $1.17.…
GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report
After disruptions at GSK plc (NYSE:GSK), supplies of rotavirus infection vaccine in children have either run out in Kenya, Tanzania,…
To Avoid Supply Crunch, FDA Temporarily Allows Higher Impurity Levels In Merck’s Diabetes Drug: Report
The FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 or NTTP, in certain samples of Merck & Co Inc's (NYSE: MRK) type 2 diabetes drug Januvia/Janumet (sitagliptin).
Ford To Raise Price Of 2023 F-150 Lightning By Up To $8500: Here’s Why
On Tuesday, the Ford Motor Company (NYSE: F) announced price hikes to its EV pickup truck, the F-150 Lightning, CNBC reported.
Amazon Receives FDA Warning Letter For OTC Mole Removal Products
The FDA’s Center for Drug Evaluation and Research released a warning letter sent to Amazon Inc’s (NASDAQ:AMZN) CEO Andy Jassy for selling…
Merck Re-enters Alzheimer’s R&D With Research Pact With Cerevance
Cerevance, a private, clinical-stage drug discovery and development company, announced a multi-year strategic research collaboration with Merck & Co Inc (NYSE:MRK). The…
AstraZeneca’s Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab…